NCT06378840View on ClinicalTrials.gov

the Predictive Value of Immune Cell in Locally Advanced Cervical Cancer

RecruitingOBSERVATIONAL
Enrollment

20

Participants

Timeline

Start Date

January 1, 2022

Primary Completion Date

December 30, 2024

Study Completion Date

December 30, 2024

Conditions
Locally Advanced Cervical CarcinomaConcurrent ChemoradiotherapyImmunotherapy
Interventions
RADIATION

Nab-paclitaxel/Platinum, Sintilimab

Sintilimab Combined With Concurrent Nab-paclitaxel/Platinum-based Chemoradiotherapy

Trial Locations (1)

200127

RECRUITING

RenJi hospital, Shanghai

All Listed Sponsors
lead

RenJi Hospital

OTHER